Navigation Links
SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
Date:1/30/2008

ST. LOUIS, Jan. 30 /PRNewswire-FirstCall/ -- SAFC(R), a member of the Sigma-Aldrich(TM) Group (Nasdaq: SIAL), has announced the second-phase of a $600,000 expansion of its solid-state services Pharmorphix(TM) research facility in Cambridge, UK, adding 7,500 sq. ft. of laboratory capacity to support this fast growing business within its SAFC Pharma(TM) focus area (http://www.safc-pharmorphix.com).

Solid-form characterization and research enhances understanding and allows modification of the physical properties of active pharmaceutical ingredients (APIs) to ensure patient benefit, optimize product development and protect intellectual property. As part of a multi-phase development program the additional, fully refitted space is scheduled for completion in the first quarter, 2008 and will augment the current 12,500 sq. ft. facility. The development includes office reorganization and will facilitate installation later this year of additional state-of-the-art spectroscopic and diffraction equipment.

SAFC Pharma Vice President of Manufacturing and European Operations, Michael Harris commented, "As new drugs and the regulatory climate continues to become more complex, testing analysis and optimization of APIs plays an increasingly key role in drug development. Through our Pharmorphix solid-state research services SAFC Pharma is a recognized and capable player in this complex field. The additional facilities reinforce our commitment to support customers in niche technologies and is expected to support SAFC business growth from Europe, the US and, increasingly, from Asia Pacific".

SAFC Pharma is a trusted leader for development and manufacturing of complex small molecule APIs and biologic drug products. This new expansion follows a recently announced $12 million expansion of SAFC Pharma's viral product manufacturing facility in Carlsbad, CA and the Pharmorphix services launch in the U.S. at its flagship high-potent manufacturing facility in Madison, WI, with new XRPD (X-ray Powder Diffraction) analytical equipment. Other recently announced investments include a $10 million expansion of commercial-scale APIs manufacturing and storage capacity, respectively, at Arklow, Ireland and Buchs, Switzerland, a $29 million potent-fermentation expansion in Jerusalem, Israel and a high-potent API conjugation suite at its St Louis, MO manufacturing campus.

About SAFC: SAFC(R) is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four focus areas -- SAFC Pharma(TM), SAFC Supply Solutions(R), SAFC Biosciences(TM), and SAFC Hitech(TM) -- and had annual sales of nearly $500 million in 2006. SAFC is one of the world's 10 largest fine chemical businesses. For more information about SAFC visit http://www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

SAFC(R) and SAFC Supply Solutions(R) are registered trademarks of Sigma-Aldrich Biotechnology L.P.

Sigma-Aldrich(TM), SAFC Pharma(TM), SAFC Biosciences(TM) and SAFC Hitech(TM) are trademarks of Sigma-Aldrich Biotechnology L.P.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology: